Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, et al. N Engl J Med 2023 Mar 15. doi: 10.1056/NEJMoa2206714.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med 2023 Mar 15. doi: 10.1056/NEJMoa2206714.
PMID: 36920778